|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/357 | |
| A61K 31/47 | |||
| A61K 45/06 | |||
| A61P 35/00 | |||
| A61P 35/02 | |||
| A61P 35/04 |
| (11) | Number of the document | 3013335 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14739971.1 |
| Date of filing the European patent application | 2014-06-26 | |
| (97) | Date of publication of the European application | 2016-05-04 |
| (45) | Date of publication and mention of the grant of the patent | 2018-11-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/JP2014/067723 |
| Date | 2014-06-26 |
| (87) | Number | WO 2014/208774 |
| Date | 2014-12-31 |
| (30) | Number | Date | Country code |
| 201361839542 P | 2013-06-26 | US |
| (72) |
NOMOTO, Kenichi, US
WU, Jiayi, US
|
| (73) |
Eisai R&D Management Co., Ltd.,
6-10, Koishikawa 4-chome Bunkyo-ku, Tokyo 112-8088,
JP
|
| (54) | COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING ERIBULIN AND LENVATINIB |
| COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING ERIBULIN AND LENVATINIB |